Guiding the immune system to cure disease

Learn more
Our mission

To advance the next generation of immunotherapies that lead T cells to gain control over disease and improve patients’ lives.

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies designed to treat immunology and inflammatory (I&I) indications by guiding T cells to overcome autoimmunity and inflammatory diseases.
About Barinthus Bio
Pipeline
News
Events & Presentations

Barinthus Biotherapeutics Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile

VTP-200 was generally well-tolerated and was administered with no product-related grade 3 unsolicited adverse events and no product-related serious adverse events (SAEs) in women with low grade human papillomavirus-related cervical lesions…

Read more

Barinthus Biotherapeutics Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

Completed Phase 1b/2a trial of VTP-300 met its primary and secondary endpoints VTP-300 is the first antigen-specific immunotherapy shown to induce sustained reductions in Hepatitis B surface antigen (HBsAg) Results will be presented at the upcoming European Association for the Study of the Liver (EASL)…

Read more

Barinthus Biotherapeutics Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

Barinthus Biotherapeutics today (March 24, 2023) announced its financial results for year end 2022 and an overview of the Company’s progress.
Read more

OUR VALUES

Helping patients and their families is the guiding principle at the heart of Barinthus Biotherapeutics.

Our values shape our culture, guide our decisions, and inspire us to achieve greatness together. At the center of our values is our dedication to patients and their families.
Our Story
Our Values
Our Careers
Patient Enquiries